Wedbush Reiterates Ratings for Multiple Biotech Firms
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: NASDAQ.COM
- Positive Outlook for arGEN-X: Wedbush analysts reiterated an Outperform rating for ArGEN-X (ARGX) with a price target of $1000, anticipating Q1 2026 earnings report, as Vyvgart generated $1.29 billion in net revenues in Q4 2025, indicating sustained growth that supports the company's long-term development in its field.
- Growth Potential for Fennec Pharma: Fennec Pharmaceuticals (FENC) was reiterated as Outperform with a price target of $13, with expectations of achieving cash flow positivity in 2026, as PEDMARK revenue reached $13.8 million in Q4 2025, reflecting a 75% year-over-year growth and showcasing the company's successful strategy in the adolescent market.
- Commercial Trajectory of Nuvation Bio: Nuvation Bio (NUVB) was reiterated as Outperform with a price target of $11, with projected Ibtrozi revenue of $21 million in Q1 2026, despite facing patient discontinuation risks, analysts believe this is a temporary issue, maintaining a positive long-term outlook.
- Steady Growth for Kiniksa Pharma: Kiniksa Pharmaceuticals (KNSA) was reiterated as Outperform with a price target raised to $58, with Arcalyst revenue expected to reach $911 million in 2026, reflecting a 34.4% year-over-year growth, demonstrating the company's strong market position in chronic autoimmune disease treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVCR
Wall Street analysts forecast NVCR stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 17.710
Low
13.50
Averages
23.58
High
39.00
Current: 17.710
Low
13.50
Averages
23.58
High
39.00
About NVCR
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovoCure CEO Frank Leonard Sells 34,273 Shares for $615,000
- Record Transaction Size: On June 4, 2026, NovoCure CEO Frank Leonard sold 34,273 shares for approximately $615,000, marking his largest individual open-market sale to date, surpassing the previous maximum of 30,196 shares, indicating confidence in liquidity management and market conditions.
- Change in Holdings: This sale represented 6.94% of Leonard's direct holdings, reducing them from 493,793 to 459,520 shares, reflecting a strategic adjustment in his ownership stake that may influence investor perceptions regarding his future intentions.
- Financial Performance: NovoCure boasts a market capitalization of $1.99 billion, with trailing twelve-month revenue increasing from around $500 million in 2023 to nearly $675 million, showcasing the company's sustained growth potential in the tumor treatment device market, despite a 63% decline in stock price over the past three years.
- Market Competitiveness: NovoCure focuses on developing and commercializing tumor-treating devices, particularly Optune for glioblastoma and Optune Pax for pancreatic cancer, with FDA approval bolstering its growth prospects, even as the overall market remains highly volatile.
See More
NovoCure CEO Sells 34,273 Shares for $615,000
- Transaction Overview: Frank Leonard, CEO of NovoCure, sold 34,273 shares on June 4, 2026, at approximately $17.93 per share, totaling around $615,000, which reduced his direct holdings by 6.94% to 459,520 shares, indicating a strategic liquidity management approach by the executive.
- Performance Metrics: Despite a 63% decline in NovoCure's stock over the past three years, with a CAGR of -28.2%, the stock has rebounded with a 30% increase year-to-date, outperforming the S&P 500's 9% gain, suggesting a positive short-term market sentiment.
- Financial Growth: The company's trailing 12-month revenue surged from approximately $500 million in 2023 to nearly $675 million, reflecting robust growth in the oncology sector, while FDA approval of its pancreatic cancer therapy, Optune Pax, further bolsters investor confidence.
- Investor Considerations: While NovoCure has shown strong performance this year, the extreme volatility in the biotech sector may lead investors to prefer diversified options like the State Street SPDR S&P Biotech ETF (XBI) for more stable returns amidst market fluctuations.
See More
Potential Analysis of Small Biotech Stocks
- FDA Approval for Axsome: Axsome Therapeutics' drug Auvelity received FDA approval for treating agitation associated with Alzheimer's disease, with a commercial launch set for June, which is expected to pivot the company from R&D to a multi-product commercial model, significantly enhancing its market share and revenue.
- NovoCure's Innovative Therapy: NovoCure's Tumor Treating Fields technology was approved by the FDA for advanced pancreatic cancer, providing a non-invasive treatment option that is projected to meet the needs of over 52,000 patients in 2026, although the company continues to invest heavily in R&D, limiting short-term profitability.
- MBX's Weight Loss Drug Development: MBX Biosciences focuses on developing long-acting protein endocrine drugs, and while it currently has no product revenue, it possesses $459.1 million in cash to fund operations through 2029, with its monthly dosing obesity candidate MBX 4291 poised to be a potential breakthrough in the market.
- Growth Opportunities in Biotech: As Axsome, NovoCure, and MBX advance their clinical trials and commercial launches, 2026 is shaping up to be a pivotal year for validating these innovative therapies, allowing investors to capitalize on the disparity between current valuations and market potential for high returns.
See More
NovoCure Q1 2026 Earnings Call Highlights
- FDA Approval and Launch: NovoCure received FDA approval for Optune Pax and launched it in Q1 2026, certifying 868 healthcare providers within seven weeks, resulting in 169 prescriptions and 90 patient starts, indicating strong market demand and rapid patient conversion capabilities.
- Revenue and Profit Outlook Upgrade: The company reported net revenue of $174 million in Q1, a 12% year-over-year increase, and raised its full-year revenue guidance to a range of $690 million to $710 million, reflecting optimism about Optune Pax's market potential.
- Global Market Growth: Active patient growth in the global market reached 17%, driven by a successful launch in Spain, demonstrating the effectiveness of the company's international expansion strategy and enhancing its global competitiveness.
- Cost and Financial Management: Despite R&D expenses of $58 million leading to a net loss of $71 million, the updated adjusted EBITDA guidance indicates potential improvement from negative $15 million to breakeven, showcasing management's confidence in future financial health.
See More
NovoCure Shares Surge 22% After Strong Q1 Revenue and Upgraded Outlook
- Strong Performance: NovoCure reported Q1 net revenues of $174.1 million, a 12% increase driven by active patient growth in European markets, significantly exceeding Wall Street expectations and demonstrating robust performance in the oncology sector.
- Upgraded Annual Outlook: The company raised its full-year revenue guidance to between $690 million and $710 million, up from the previous forecast of $675 million to $705 million, reflecting increased confidence in future performance.
- Positive Market Reaction: NovoCure's shares surged nearly 22% on Thursday, trading at $14.58, with a year-to-date gain of over 12%, outperforming the broader S&P 500 Index's 4% rise, indicating strong investor optimism about the company's prospects.
- Significant Clinical Progress: In March, NovoCure announced that its Tumor Treating Fields device met the primary endpoint in its Phase 2 PANOVA-4 trial for specific pancreatic cancer patients, with FDA approval of Optune Pax expected to further expand its market, boosting investor confidence.
See More
NovoCure Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: NovoCure reported a Q1 GAAP EPS of -$0.62, missing estimates by $0.11, while revenue reached $174.1 million, reflecting a 12.3% year-over-year growth and exceeding market expectations by $6.33 million, indicating strong revenue performance.
- Adjusted EBITDA Status: The adjusted EBITDA for the quarter was $(0.3) million, showing an improvement from previous expectations, which highlights the company's efforts in cost control and operational efficiency despite still being in negative territory.
- Patient Growth: As of March 31, 2026, there were 4,791 active patients on TTFields therapy globally, with Optune Gio's active patients increasing by 9% to 4,543, demonstrating the growing market acceptance and demand for the company's products.
- 2026 Financial Guidance: NovoCure updated its financial guidance for 2026, projecting total net revenue between $690 million and $710 million, an increase from prior guidance, reflecting the company's strengthened confidence in future performance.
See More
NovoCure CEO Frank Leonard Sells 34,273 Shares for $615,000
- Record Transaction Size: On June 4, 2026, NovoCure CEO Frank Leonard sold 34,273 shares for approximately $615,000, marking his largest individual open-market sale to date, surpassing the previous maximum of 30,196 shares, indicating confidence in liquidity management and market conditions.
- Change in Holdings: This sale represented 6.94% of Leonard's direct holdings, reducing them from 493,793 to 459,520 shares, reflecting a strategic adjustment in his ownership stake that may influence investor perceptions regarding his future intentions.
- Financial Performance: NovoCure boasts a market capitalization of $1.99 billion, with trailing twelve-month revenue increasing from around $500 million in 2023 to nearly $675 million, showcasing the company's sustained growth potential in the tumor treatment device market, despite a 63% decline in stock price over the past three years.
- Market Competitiveness: NovoCure focuses on developing and commercializing tumor-treating devices, particularly Optune for glioblastoma and Optune Pax for pancreatic cancer, with FDA approval bolstering its growth prospects, even as the overall market remains highly volatile.
See More
NovoCure CEO Sells 34,273 Shares for $615,000
- Transaction Overview: Frank Leonard, CEO of NovoCure, sold 34,273 shares on June 4, 2026, at approximately $17.93 per share, totaling around $615,000, which reduced his direct holdings by 6.94% to 459,520 shares, indicating a strategic liquidity management approach by the executive.
- Performance Metrics: Despite a 63% decline in NovoCure's stock over the past three years, with a CAGR of -28.2%, the stock has rebounded with a 30% increase year-to-date, outperforming the S&P 500's 9% gain, suggesting a positive short-term market sentiment.
- Financial Growth: The company's trailing 12-month revenue surged from approximately $500 million in 2023 to nearly $675 million, reflecting robust growth in the oncology sector, while FDA approval of its pancreatic cancer therapy, Optune Pax, further bolsters investor confidence.
- Investor Considerations: While NovoCure has shown strong performance this year, the extreme volatility in the biotech sector may lead investors to prefer diversified options like the State Street SPDR S&P Biotech ETF (XBI) for more stable returns amidst market fluctuations.
See More
Potential Analysis of Small Biotech Stocks
- FDA Approval for Axsome: Axsome Therapeutics' drug Auvelity received FDA approval for treating agitation associated with Alzheimer's disease, with a commercial launch set for June, which is expected to pivot the company from R&D to a multi-product commercial model, significantly enhancing its market share and revenue.
- NovoCure's Innovative Therapy: NovoCure's Tumor Treating Fields technology was approved by the FDA for advanced pancreatic cancer, providing a non-invasive treatment option that is projected to meet the needs of over 52,000 patients in 2026, although the company continues to invest heavily in R&D, limiting short-term profitability.
- MBX's Weight Loss Drug Development: MBX Biosciences focuses on developing long-acting protein endocrine drugs, and while it currently has no product revenue, it possesses $459.1 million in cash to fund operations through 2029, with its monthly dosing obesity candidate MBX 4291 poised to be a potential breakthrough in the market.
- Growth Opportunities in Biotech: As Axsome, NovoCure, and MBX advance their clinical trials and commercial launches, 2026 is shaping up to be a pivotal year for validating these innovative therapies, allowing investors to capitalize on the disparity between current valuations and market potential for high returns.
See More
NovoCure Q1 2026 Earnings Call Highlights
- FDA Approval and Launch: NovoCure received FDA approval for Optune Pax and launched it in Q1 2026, certifying 868 healthcare providers within seven weeks, resulting in 169 prescriptions and 90 patient starts, indicating strong market demand and rapid patient conversion capabilities.
- Revenue and Profit Outlook Upgrade: The company reported net revenue of $174 million in Q1, a 12% year-over-year increase, and raised its full-year revenue guidance to a range of $690 million to $710 million, reflecting optimism about Optune Pax's market potential.
- Global Market Growth: Active patient growth in the global market reached 17%, driven by a successful launch in Spain, demonstrating the effectiveness of the company's international expansion strategy and enhancing its global competitiveness.
- Cost and Financial Management: Despite R&D expenses of $58 million leading to a net loss of $71 million, the updated adjusted EBITDA guidance indicates potential improvement from negative $15 million to breakeven, showcasing management's confidence in future financial health.
See More
NovoCure Shares Surge 22% After Strong Q1 Revenue and Upgraded Outlook
- Strong Performance: NovoCure reported Q1 net revenues of $174.1 million, a 12% increase driven by active patient growth in European markets, significantly exceeding Wall Street expectations and demonstrating robust performance in the oncology sector.
- Upgraded Annual Outlook: The company raised its full-year revenue guidance to between $690 million and $710 million, up from the previous forecast of $675 million to $705 million, reflecting increased confidence in future performance.
- Positive Market Reaction: NovoCure's shares surged nearly 22% on Thursday, trading at $14.58, with a year-to-date gain of over 12%, outperforming the broader S&P 500 Index's 4% rise, indicating strong investor optimism about the company's prospects.
- Significant Clinical Progress: In March, NovoCure announced that its Tumor Treating Fields device met the primary endpoint in its Phase 2 PANOVA-4 trial for specific pancreatic cancer patients, with FDA approval of Optune Pax expected to further expand its market, boosting investor confidence.
See More
NovoCure Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: NovoCure reported a Q1 GAAP EPS of -$0.62, missing estimates by $0.11, while revenue reached $174.1 million, reflecting a 12.3% year-over-year growth and exceeding market expectations by $6.33 million, indicating strong revenue performance.
- Adjusted EBITDA Status: The adjusted EBITDA for the quarter was $(0.3) million, showing an improvement from previous expectations, which highlights the company's efforts in cost control and operational efficiency despite still being in negative territory.
- Patient Growth: As of March 31, 2026, there were 4,791 active patients on TTFields therapy globally, with Optune Gio's active patients increasing by 9% to 4,543, demonstrating the growing market acceptance and demand for the company's products.
- 2026 Financial Guidance: NovoCure updated its financial guidance for 2026, projecting total net revenue between $690 million and $710 million, an increase from prior guidance, reflecting the company's strengthened confidence in future performance.
See More
